Evelyn Berger–Sieczkowski

Frequency and Characterization of Movement Disorders in Anti-IgLON5 Disease

Carles Gaig, Yaroslau Compta, Anna Heidbreder et al. · Neurology · 2021 · 112 citations · Full text

Medicine, Neurology, Autoimmunity +11

A phase I study assessing the safety, tolerability, immunogenicity, and low-density lipoprotein cholesterol-lowering activity of immunotherapeutics targeting PCSK9

Markus Zeitlinger, Martin Bauer, Roman Reindl‐Schwaighofer et al. · European Journal of Clinical Pharmacology · 2021 · 57 citations · Full text

Pharmacy, Immunology, Pharmacology +17

Double impact on p‐glycoprotein by statins enhances doxorubicin cytotoxicity in human neuroblastoma cells

Evelyn Berger–Sieczkowski, Claudia Lehner, Peter F. Ambros et al. · International Journal of Cancer · 2009 · 54 citations · Full text

Medicine, Oncology, Pharmacology +16

Analysis of inflammatory markers and tau deposits in an autopsy series of nine patients with anti-IgLON5 disease

Evelyn Berger–Sieczkowski, Verena Endmayr, Carmen Haider et al. · Acta Neuropathologica · 2023 · 42 citations · Full text

Life Sciences, Neurology, Pathology +16

Neuropathological spectrum of anti-IgLON5 disease and stages of brainstem tau pathology: updated neuropathological research criteria of the disease-related tauopathy

Ellen Gelpí, Raphael Reinecke, Carles Gaig et al. · Acta Neuropathologica · 2024 · 34 citations · Full text

Life Sciences, Neurology, Neuroscience +17